U.S. Congress - S.1423 Preserving Access to Orphan Drugs Act of 2011
S.1423 - Preserving Access to Orphan Drugs Act of 2011
A bill to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers. view all titles (2)
All Bill Titles
- Official: A bill to clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers. as introduced.
- Short: Preserving Access to Orphan Drugs Act of 2011 as introduced.
This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.
Bill's Views
- Today: 3
- Past Seven Days: 10
- All-Time: 1,241
|
|
|
|
|
|
|
|
Committees
Official Summary
7/27/2011--Introduced.Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diOfficial Summary
7/27/2011--Introduced.Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA....Read the Rest
Organizations Supporting S.1423
- Alpha 1 Foundation
- Immune Deficiency Foundation
- Plasma Protein Therapeutics Association
Organizations Opposing S.1423
- None via MapLight at this time.
See the money trail behind this bill for more info on how campaign contributions may be influencing senators' and representatives' votes.
Vote on This Bill
-
Share This Bill
More Share via Email
